A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 58-64

  Tolcher, Anthony W ^a   Bendell, J C ^b   Papadopoulos, K P ^a   Burris, H A ^b   Patnaik, A ^a   Jones, S F ^b   Rasco, D ^a   Cox, D S ^c   Durante, M ^c   Bellew, K M ^d   Park, J ^c   Le, N T ^e   Infante, J R ^b  

^a South Texas Accelerated Research Therapeutics   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Advanced solid tumors; Everolimus; MEK inhibitor; MTOR inhibitor; Pancreatic cancer; Trametinib

Indexed keywords

EVEROLIMUS; TRAMETINIB; ANTINEOPLASTIC AGENT; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DECREASED APPETITE; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SINGLE BLIND PROCEDURE; SOLID TUMOR; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FEMALE; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922515314     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu482     Document Type: Article

References (20)

1. Young A, Lyons J, Miller AL et al. Ras signaling and therapies. Adv Cancer Res 2009; 102: 1-17.
2. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
3. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
4. Arrington AK, Heinrich EL, Lee W et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012; 13: 12153-12168.
5. Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
6. Chappell WH, Steelman LS, Long JM et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-164.
7. Saini KS, Loi S, de Azambuja E et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 2013; 39: 935-946.
8. Manegold PC, Paringer C, Kulka U et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008; 14: 892-900.
9. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
10. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
11. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132.
12. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
13. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
14. Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 773-781.
15. Jing J, Greshock J, Holbrook JD et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 2012; 11: 720-729.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
17. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. (11 November 2014, date last accessed).
18. Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17: 135-144.
19. Infante JR, Patnaik A, Jones SF et al. A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: interim results. Mol Cancer Ther 2011; 10: Abstr B128.
20. Novartis Pharmaceuticals Corporation. Afinitor (everolimus [tablets]) [package insert]. 2012.